Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaboNivoIpi in Radioiodine-Refractory Differentiated Thyroid Cancer
NCT03914300Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in differentiated thyroid cancer (DTC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 6 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03914300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914300.